A 30 minute conversation · no hard pitch

Thirty minutes on your asset, with the person who would do the work.

If a specific asset is on your desk, we spend the time on it: who adopts it in real practice, the target population you can defend, and how it clears the European reimbursement gate.

Sébastien Petitet

Founder · SPinsights Consulting

Thirty years inside Baxter, Biogen, Chiesi, Genzyme and Merck, building medical affairs and market access from zero.

Prefer email? sebastien@spinsights.eu

What SPinsights is

One operator, accountable from preclinical to early access.

SPinsights maps who will adopt a therapy in real multidisciplinary practice, qualifies and prioritises the experts who decide access, defines the target population you can defend in front of them, and reads the European market access and early access path before submission. Not advising on medical affairs and market access. Building them, including the real-world evidence and health economics that payers expect.

Why this work

Turning a mechanism into an actual prescription.

You raised on the strength of the mechanism, and the science holds. The next round will not ask about your biology. It asks who adopts this in a multidisciplinary practice, what the target population is, how it fits the patient journey, and whether a well-defined unmet need would push Europe to grant early access before approval. The first time a patient received an advanced therapy taken through early access, the real job was clear: turning a mechanism into a prescription, in a real clinic, in a specific country.

5 therapies taken through European early access, including 3 advanced therapy medicinal products.
First patients treated in Belgium and France.
National-authority hearings prepared and defended.
Paris Saclay: programmes selected within the Cancer Cluster.
Expert and site selection for scientific boards and trials in cell, immuno and gene therapy.
Development plans structured for CAR-T multi-indication and PDAC programmes.

Who this is for

Senior judgment, before you can justify a CMO.

A fit

Early-stage oncology and rare-disease biotechs, usually scientific founders who need senior judgment before hiring a chief medical officer. Also pharma clinical development, market access and medical affairs teams preparing future launches.

Not a fit

If you want a large agency with a junior team, or a logo on a slide. Clients value discretion and compliance. Your name stays yours, by design.

When a European launch is on your roadmap and the access path is not clear yet.

Twenty to thirty minutes, on your asset, with the person who would do the work.

Or email sebastien@spinsights.eu